Lee Rex H, Truong Angeline, Wu Xin, Kang Hyunseok, Algazi Alain P, El-Sayed Ivan H, George Jonathan R, Heaton Chase M, Ryan William R, Ha Patrick K, Wai Katherine C
Department of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA.
Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
Head Neck. 2024 Jan;46(1):129-137. doi: 10.1002/hed.27565. Epub 2023 Oct 28.
A minority of patients with recurrent/metastatic (R/M) salivary gland cancers (SGCs) benefit from immune checkpoint inhibitors (ICIs), necessitating reliable biomarkers for ICI response prediction.
Retrospective observational study of R/M SGC patients treated with pembrolizumab between 2016 and 2022, with a primary outcome of 6-month progression-free survival (PFS) and secondary outcome of 2-year overall survival (OS). Univariate and multivariable Cox proportional hazards models were employed.
Twenty R/M SGC patients were included. After adjustment, NLR as a continuous variable was independently associated with 6-month PFS (HR 1.30, 95% CI 1.10-1.54, p = 0.002) and 2-year OS (HR 1.33, 95% CI 1.07-1.66, p = 0.010). Similarly, NLR ≥ 5 was associated with higher hazards of progression at 6 months (HR 12.85, 95% CI 2.17-76.16, p = 0.005) and death at 2 years (HR 11.25, 95% CI 1.67-75.77, p = 0.013).
Higher pretreatment NLR was independently associated with inferior 6-month PFS and 2-year OS in pembrolizumab-treated R/M SGC patients.
少数复发/转移性（R/M）涎腺癌（SGC）患者可从免疫检查点抑制剂（ICI）中获益，因此需要可靠的生物标志物来预测ICI反应。
对2016年至2022年间接受帕博利珠单抗治疗的R/M SGC患者进行回顾性观察研究，主要结局为6个月无进展生存期（PFS），次要结局为2年总生存期（OS）。采用单变量和多变量Cox比例风险模型。
纳入20例R/M SGC患者。调整后，作为连续变量的中性粒细胞与淋巴细胞比值（NLR）与6个月PFS（风险比[HR]1.30，95%置信区间[CI]1.10-1.54，p = 0.002）和2年OS（HR 1.33，95%CI 1.07-1.66，p = 0.010）独立相关。同样，NLR≥5与6个月时更高的进展风险（HR 12.85，95%CI 2.17-76.16，p = 0.005）和2年时的死亡风险（HR 11.25，95%CI 1.67-75.77，p = 0.013）相关。
在接受帕博利珠单抗治疗的R/M SGC患者中，较高的治疗前NLR与较差的6个月PFS和2年OS独立相关。
